Hemostemix Appoints Robert Achtymichuk as Vice President, Business DevelopmentMarch 31, 2016
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV: HEM) (OTCQX: HMTXF), a clinical-stage autologous cell therapy company, announced today the appointment of Robert Achtymichuk as its new Vice President, Business Development.
In this role, Robert will lead all business development initiatives, including partner and investor engagement and will collaborate with the senior leadership team to develop and execute strategies that drive continued growth to ensure the company continues to evolve and generate value for its shareholders.
“The appointment of Mr. Achtymichuk to this important position reflects our ongoing efforts to further develop our business and enhance our ongoing investor relations efforts, as well as foster strategic partnerships. “I am very pleased that he has assumed this important position,” said Dr. Elmar Burchardt, president and CEO of Hemostemix.
Robert holds a degree in petroleum engineering from the University of Alberta and a Partners, Directors and Senior Officers designation from the Canadian Securities Institute. Before joining Hemostemix, he spent over 29 years in the financial investment industry, including nine years as a Vice President at Haywood Securities. In his new role as Vice President, Business Development, Robert will apply his substantial knowledge and experience to the advancement of business goals and to the cultivation of partnerships.
“As a long-time supporter of Hemostemix, I look forward to working with the company’s exceptional team of scientists and professionals. This highly skilled group is dedicated to completing the ongoing phase 2 clinical trials and meeting other key milestones. I am strongly committed to raising the Hemostemix profile and leading business development,.”, stated Robert.
Hemostemix is a public clinical-stage biotechnology company that develops and commercializes innovative blood-derived cell therapies for medical conditions not adequately addressed by current treatments. It is the first clinical-stage biotech company to test a stem-cell therapy in an international, multicenter, phase 2 clinical trial for patients with critical limb ischemia (CLI), a severe form of peripheral artery disease (PAD) caused by reduced blood flow to the legs. The phase 2 trial targets a participant’s diseased tissue with proprietary cells grown from his or her blood that are capable of supporting the formation of new blood vessels. Hemostemix currently enrolls participants in the phase 2 trial at four sites in South Africa and two sites in Canada. The Company recently received FDA clearance to commence clinical trials in the United States.
Neither the TSX Venture Exchange, Inc. nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “projects,” “potential,” and similar expressions, or that events or conditions “will,” “would,” “may,” “could,” or “should” occur. Although Hemostemix believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates, and opinions of Hemostemix management on the date such statements were made. Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events, or otherwise.
View All News & Media